Pruritus

Pruritus is the sensation of itch, and like pain, it is a symptom that can arise from many different underlying processes rather than a single disease. Acute, localized itch (an insect bite, a brief contact reaction) rarely needs formal work-up. Chronic pruritus -- itch lasting six weeks or longer -- is different: it can be driven by a primary skin disease, but it is also a recognized presenting feature of systemic disease (renal, hepatic, hematologic, endocrine, or malignant), of a medication, of a neuropathic process, or of a psychiatric condition, and in a subset of patients no cause is ever identified despite a thorough work-up.^[1] The management principle that follows from this is simple to state and easy to skip in practice: identify and treat the underlying cause whenever one exists, and reserve purely symptomatic antipruritic therapy -- matched to the itch's likely mechanism, not applied reflexively -- for itch that persists despite this, or for which no treatable cause is found.

What to look for on skin examination

The single most important branch point on examination is whether there is a primary skin lesion that explains the itch, or only secondary changes caused by scratching. Primary dermatologic disease (eczema, psoriasis, scabies, urticaria, a drug eruption) has its own characteristic morphology and is addressed as that specific diagnosis. When the skin shows only excoriations, lichenification (thickened, leathery skin from chronic rubbing), prurigo nodules, or is entirely normal, the itch itself is the primary problem and the visible skin changes are secondary to scratching -- this pattern should prompt a search for a systemic, neuropathic, psychogenic, or drug-related cause rather than a dermatologic diagnosis. Excoriation and lichenification are easy to misread as a primary inflammatory skin condition when they are actually the downstream result of chronic pruritus from an entirely different cause.

• Older age -- both because xerosis (dry skin) becomes more common and because the prevalence of chronic kidney disease, malignancy, and polypharmacy all rise with age.
• Known chronic kidney disease, particularly hemodialysis-dependent end-stage renal disease.
• Known cholestatic or other chronic liver disease.
• Hematologic conditions -- iron deficiency, polycythemia vera, lymphoma (particularly Hodgkin lymphoma), and other myeloproliferative or lymphoproliferative disorders.
• Thyroid dysfunction, either hyperthyroidism or hypothyroidism.
• HIV infection.
• New or recently changed medication, especially an opioid, or any of the drug classes listed in Common Errors to Avoid.
• Personal or family history of atopic disease.
• Underlying psychiatric illness, particularly depression, anxiety, or a somatoform pattern.
• Xerosis from any cause, including low ambient humidity, frequent hot showers/baths, and harsh or fragranced cleansing products.
• Pregnancy -- a distinct set of pregnancy-specific pruritic conditions exists and needs its own targeted evaluation; see Special Populations.

Differential diagnosis of systemic causes

This is the core of the pharmacist-relevant work-up once a primary skin disease has been reasonably excluded on examination.

History

• Onset, duration, distribution (localized vs. generalized), and any temporal pattern (constant, worse at night, worse after bathing).
• Full skin-care routine -- cleansing products, topical products applied, frequency and temperature of showers/baths, use of hot tubs.
• Complete prescription, nonprescription, and recreational/illicit drug history, including anything started or changed in the weeks before the itch began.
• Directed systemic-symptom review: unintentional weight loss, fevers, night sweats, fatigue, cold/heat intolerance, change in urine or stool colour.
• Relevant travel or immigration history, given that some parasitic causes of itch are geographically restricted.
• Psychosocial stressors, mood, anxiety, and sleep quality -- both as possible contributors and as consequences of chronic itch.

Physical examination

• Full skin examination for a primary rash or lesion versus only secondary changes (excoriation, lichenification, prurigo nodules) or normal-appearing skin.
• Test for dermatographism (stroke the skin firmly and look for a raised wheal a few minutes later) -- a positive test identifies a histamine-mediated itch mechanism that typically responds to antihistamines.
• Look specifically for burrows to evaluate for scabies.
• Assess for jaundice or abnormal pigmentation, lymphadenopathy, and hepatosplenomegaly.

When laboratory testing is, and is not, indicated

Laboratory work-up is appropriate once a primary dermatologic cause has been reasonably excluded, not as a routine reflex in every patient with itch -- a patient with a clear primary dermatosis should be treated for that diagnosis rather than sent for a broad systemic panel. When systemic work-up is indicated: CBC with differential, fasting glucose, liver function tests including bilirubin, renal function tests, chest x-ray, and HIV testing form the reasonable initial panel; TSH, calcium, serum protein electrophoresis, ferritin, and stool for ova and parasites (with a relevant travel history) can be added if this initial work-up is unrevealing and itch persists.^[1]

• Identify and treat, or refer for treatment of, any underlying dermatologic, systemic, or drug-related cause -- this takes priority over purely symptomatic antipruritic therapy whenever a cause exists.
• Reduce itch intensity and frequency to a level the patient finds tolerable, recognizing that complete elimination is not always achievable, particularly for pruritus of unknown origin.
• Break the scratch-itch cycle to prevent secondary skin damage -- excoriation, lichenification, prurigo nodularis, and secondary skin infection.
• Restore sleep quality, since itch is frequently worse at night and poor sleep in turn lowers the itch threshold.
• Select the antipruritic option matched to the itch's likely mechanism rather than defaulting to the same agent for every patient, since efficacy differs substantially by cause.
• Minimize treatment-related harm -- avoid prolonged topical corticosteroid use where there is no inflammatory component, and avoid escalating to a systemic agent with real toxicity before simpler, safer measures have had an adequate trial.

• Hydrate the skin. Dry skin (xerosis) from low ambient humidity, hot showers, or harsh soap frequently worsens itch of any cause. Use a fragrance-free, pH-neutral synthetic detergent cleanser rather than traditional alkaline soap, take lukewarm (not hot) showers or baths limited to 5-10 minutes, and use an indoor humidifier in dry conditions.
• Apply moisturizer immediately after bathing, while the skin is still slightly damp, to trap hydration. Ointment-based moisturizers are more occlusive and effective for very dry skin; creams are lighter and often better tolerated for daily use over larger areas.
• Minimize friction and irritation. Pat the skin dry rather than rubbing; apply topical products by dabbing. Choose soft, loose-fitting cotton clothing and avoid wool or rough synthetic fabrics. Rinse laundry detergent thoroughly and use fragrance-free laundry and personal-care products.
• Avoid known aggravating factors -- prolonged hot showers/baths, hot tubs and saunas, spicy foods, caffeine, alcohol, and excessive heat/humidity. A brief symptom diary can help an individual patient identify their own specific triggers.
• Break the scratch-itch cycle. Scratching provides brief relief but perpetuates and worsens itch, and causes the secondary skin damage (excoriation, lichenification, infection risk) that then itches on its own. Keep fingernails and toenails short and smooth; a light covering of clothing over an itchy area reduces unintentional scratching; cool compresses applied for about 20 minutes, several times daily, help acute localized flares.
• Address nighttime itch specifically, since pruritus is frequently worse at night. Apply moisturizer or a topical antipruritic just before bed, use lightweight bedclothes, keep the bedroom cool, and consider a sedating antihistamine at bedtime when sedation itself (not a true antipruritic effect) is the goal -- see Pharmacologic Treatment Options.
• Colloidal oatmeal bath preparations can be soothing as an adjunct for generalized itch.
• For patients with a substantial psychological or stress component, structured approaches such as habit-reversal training, relaxation techniques, and education on the itch-scratch cycle can meaningfully help, though access to these programs is often limited.

Breastfeeding

General measures remain first-line, and care should be taken to keep an infant's skin away from any area treated with a topical product. Colloidal oatmeal baths, and limited topical menthol/camphor use, are considered low risk given minimal systemic absorption. Oral second-generation antihistamines (cetirizine, desloratadine, fexofenadine, loratadine) are compatible with breastfeeding. Occasional use of a first-generation antihistamine is generally fine; larger or prolonged doses can cause infant drowsiness or reduce milk supply. Cholestyramine and colestipol are considered safe. Gabapentin produces low levels in breast milk, though infant monitoring is reasonable; data on pregabalin are more limited. Rifampin levels in milk are low and it is used routinely in breastfeeding patients being treated for tuberculosis. Naltrexone transfers minimally into breast milk and is not generally considered a reason to avoid breastfeeding, though data remain limited. There is no safety information available for difelikefalin in breastfeeding.

Pediatrics

Camphor-containing topical products should be avoided in children under 2 years of age -- camphor absorbed through infant skin has been associated with systemic toxicity, including seizures. Topical corticosteroid potency and duration should be minimized in children generally, given a higher surface-area-to-weight ratio and correspondingly greater systemic absorption risk than in adults.

Renal and hepatic impairment

Gabapentin and pregabalin both require dose reduction in renal impairment given renal elimination -- confirm current renal function before dosing and reduce accordingly; this is especially relevant since renal impairment is itself one of the leading indications for a gabapentinoid in this chapter. Rifampin requires baseline and periodic liver enzyme monitoring given its hepatotoxicity risk, and should be avoided or used with particular caution in patients with significant baseline hepatic impairment -- discuss with the prescribing team when itch is hepatic in origin and the liver is already compromised.

Reassess itch severity, sleep quality, and overall impact on daily function at every follow-up -- these are the practical measures of whether treatment is working, more so than any single lab value. Confirm adherence to general skin-care measures before assuming a pharmacologic option has failed. Monitor for adverse effects specific to the agent in use: skin atrophy and thinning with topical corticosteroid use (examine the treated area), renal function and sedation/dizziness with gabapentinoid dosing, liver enzymes with rifampin or naltrexone, and for signs of opioid withdrawal if naltrexone is started in a patient who may be taking an opioid for another reason. Periodically trial tapering or discontinuing symptomatic antihistamine therapy to confirm ongoing need rather than continuing indefinitely by default. Watch for emergence of red-flag features that were not present at initial assessment -- new weight loss, jaundice, or lymphadenopathy warrants the same urgent work-up described in Red Flags & Refer even in a patient already being treated symptomatically.

1. Reconfirm the working diagnosis and that adherence to the current regimen, including general skin-care measures, has genuinely been adequate before concluding a drug has failed.
2. Confirm a topical corticosteroid is not being used for itch without an inflammatory component -- this will not work and should be stopped rather than escalated.
3. Re-review the medication list for a drug started or changed around the time itch began, including anything added since the last visit.
4. If no systemic work-up has yet been done, or it was limited, revisit the differential-diagnosis table in Assessment & Diagnosis and pursue directed testing based on any clues that have since emerged.
5. If a topical-only approach has had an adequate trial without benefit, move to a systemic agent selected by the itch's likely mechanism -- gabapentinoid for neuropathic/uremic, bile acid sequestrant progressing to rifampin then naltrexone for cholestatic, updosed antihistamine for histamine-mediated, mirtazapine for nocturnal/refractory.
6. If a gabapentinoid has not yet been tried for a neuropathic or uremic pattern, or the itch is not clearly histamine-mediated, this is a reasonable next step given genuine trial evidence versus continued reliance on an antihistamine.
7. Refer to dermatology for consideration of phototherapy, or to the relevant specialist (nephrology, hepatology, hematology, psychiatry) when the itch is clearly tied to their domain and remains refractory.
8. For pruritus that remains unexplained and refractory despite a complete, guideline-directed work-up and adequate sequential drug trials, refer for specialist reassessment of the diagnosis itself -- pruritus of unknown origin is a diagnosis of exclusion that should be revisited periodically, not a permanent label applied once and never reconsidered.

• Reflexively prescribing a nonsedating antihistamine for chronic itch that is not histamine-mediated -- the evidence for benefit outside urticaria/dermatographism/mastocytosis is weak, and this delays effective treatment.^[1]
• Using a topical corticosteroid for itch without visible inflammation -- it will not relieve the itch and exposes the patient to atrophy risk for no benefit.
• Assuming itch without a rash cannot be drug-induced -- several important causes of drug-induced pruritus, including opioids, occur without any visible skin eruption.
• Stopping the diagnostic work-up after a single negative skin examination when systemic clues (weight loss, jaundice, lymphadenopathy, abnormal labs) are present -- these need active pursuit, not reassurance.
• Ordering a broad systemic panel in a patient who already has a clear primary dermatologic explanation on examination -- unnecessary and delays the correct, targeted treatment.
• Using a camphor-containing product in a child under 2 years of age.
• Starting naltrexone in a patient taking an opioid analgesic without checking first -- precipitates withdrawal.
• Neglecting fat-soluble vitamin status with prolonged bile acid sequestrant use.
• Missing intrahepatic cholestasis of pregnancy in a pregnant patient with new pruritus, especially a palms/soles pattern worse at night -- this is a red flag requiring prompt obstetric assessment, not routine symptomatic treatment.
• Not counselling on the scratch-itch cycle and practical measures (short nails, cool environment, avoiding hot showers) -- these meaningfully help regardless of the underlying cause and are frequently skipped in favour of jumping straight to a prescription.

How to use this table: doses are adult doses and require patient-specific confirmation, including renal/hepatic adjustment. Select any drug name to open its complete Pharmasist Drug Database page. Every agent here is grouped by the itch mechanism it is actually evidence-based for -- see Choose Initial Treatment before selecting from this table.^[1]

Topical antipruritics / counterirritants

First-choice topical option for mild, non-inflammatory itch of any origin.

Topical corticosteroids

Only appropriate when the itch has a visible inflammatory component (redness, sometimes tenderness). Choice of potency depends on site, severity, and anticipated duration of use; not recommended for chronic, generalized, or long-term use.

Topical calcineurin inhibitors

Non-steroidal option for inflammatory itch, particularly useful on sensitive sites where a corticosteroid should be minimized.

Substance P / neurogenic-acting topical agents

For genuinely localized neuropathic itch, or as an adjunct in other itch types; must be used consistently to work.

Oral antihistamines -- nonsedating

Reliably effective only for histamine-mediated itch (urticaria, dermatographism, mastocytosis); weak evidence for benefit in most other chronic pruritus.

Evidence note: updosing a nonsedating antihistamine up to 4-fold for an inadequate response is supported by current international urticaria guidance.^[2]

Oral antihistamines -- sedating

Benefit for non-histaminergic chronic itch, particularly at night, is thought to come from sedation rather than a true antipruritic effect -- set expectations accordingly.

Gabapentinoids

Genuine evidence base for neuropathic and uremic itch, unlike antihistamines for these causes; both require renal dose adjustment.

Evidence note: a systematic review of gabapentin specifically for uremic pruritus in hemodialysis patients supports starting at a low dose and titrating cautiously to balance effectiveness against adverse events^[3]; a broader systematic review and meta-analysis of 27 trials found a significant reduction in pruritus with gabapentin/pregabalin compared with control, with a favourable safety profile.^[4]

Bile acid sequestrants

First-line systemic agents for cholestatic/hepatic pruritus.

Evidence note: bile acid sequestrant dosing for cholestatic pruritus reflects current AASLD practice guidance.^[5]

Rifamycin (cholestatic pruritus, refractory)

Second-line, after an adequate trial of a bile acid sequestrant; requires monitoring given hepatotoxicity risk.

Evidence note: rifampin dosing for cholestatic pruritus reflects current AASLD practice guidance.^[5]

Opioid receptor modulators

For cholestatic itch refractory to the above (naltrexone), and for uremic itch specifically approved for hemodialysis patients (difelikefalin).

Evidence note: naltrexone dosing for cholestatic pruritus reflects current AASLD practice guidance^[5]; difelikefalin dosing reflects its Health Canada-approved regimen for hemodialysis-associated pruritus.^[6]

Antidepressants and serotonin-pathway agents

Options for nocturnal, cholestatic, paraneoplastic, or otherwise refractory itch; evidence is generally from smaller studies than for the agents above.

Evidence note: mirtazapine dosing is based on small pilot-study evidence for nocturnal pruritus^[7]; sertraline is supported by current AASLD practice guidance for cholestatic pruritus^[5]; paroxetine dosing reflects a randomized controlled trial specifically in non-dermatological pruritus.^[8]